Anti-amyloid therapies signal potential for early Alzheimer’s disease
By GlobalData Healthcare 30 Jun 2021 (Last Updated June 30th, 2021 15:07)
On June 24, the FDA granted breakthrough therapy designation (BTD) to two pipeline drugs: Eisai and Biogen’s lecanemab (BAN2401) and Eli Lilly’s donanemab for the treatment of Alzheimer’s disease (AD).
Credit: Robert Kneschke / Shutterstock.
Share Article
On June 24, the FDA granted breakthrough therapy designation (BTD) to two pipeline drugs: Eisai and Biogen’s lecanemab (BAN2401) and Eli Lilly’s donanemab for the treatment of Alzheimer’s disease (AD). Currently, the AD market is dominated by symptom-based therapies with modest efficacy. Earlier this month, Biogen’s Aduhelm (aducanumab) received FDA approval, and thus it is the first and only approved AD disease-modifying treatment (DMT). GlobalData forecasts that Aduhelm will generate $5.5B globally by
Breakthrough therapy designated for Lilly s investigational Alzheimer s drug donanemab
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Lilly s donanemab receives U S FDA s Breakthrough Therapy designation for treatment of Alzheimer s disease
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.